Anjaneyulu Muragundla, Chopra Kanwaljit
Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
Ren Fail. 2005;27(3):335-44.
Diabetic nephropathy is the main cause of end stage renal damage. Oxidative stress is involved in the etiology of diabetic nephropathy and intracellular calcium is reported to play a considerable role in the development of renal damage in the diabetic kidney. Calcium antagonism can slow the progression of renal impairment in diabetes. The present study was thus designed to examine the effect of a nondihydropyridine calcium channel blocker, diltiazem, on renal function, oxidative stress, and nitric oxide (NO) release in streptozotocin (STZ)-induced diabetic rats. Diabetes was induced by a single intraperitoneal injection of STZ (65 mg/kg) in rats. After 4 weeks of STZ injection, the rats were divided in to four groups: control rats, diabetic rats treated with saline, and two groups of diabetic rats treated with diltiazem (5 and 10 mg/kg, i.p, respectively) for 8 weeks starting from 4 weeks after STZ injection. Renal function was assessed by creatinine, blood urea nitrogen, creatinine clearance, and urea clearance. Oxidative stress was measured by renal malondialdehyde (MDA), reduced glutathione (GSH), superoxide dismutase (SOD), and catalase. We also measured renal nitrite levels. At the end of the 8 weeks, diabetic rats exhibited renal dysfunction as evidenced by reduced creatinine and urea clearance along with enhanced albumin excretion rate as compared with control rats. Biochemical analysis of kidneys revealed a marked increase in oxidative stress demonstrated by increased lipid peroxidation and decreased activities of key antioxidant enzymes, GSH, SOD, and catalase in diabetic rats. Release of NO also significantly higher in diabetic rats than controls. Chronic treatment with diltiazem in diabetic rats significantly attenuated both renal dysfunction and oxidative stress along with increased NO levels as compared with untreated diabetic rats. The kidneys of diabetic rats showed morphological changes such as hyaline casts, glomerular thickening, and moderate interstitial fibrosis and arteriolopathy, whereas diltiazem administration markedly prevented diabetic-induced renal morphological alterations. The present study suggests that oxidative stress/nitrosative stress is increased in the diabetic kidney and calcium channel blockage can prevent these changes. The results also suggest that in STZ-induced diabetic rats, the protective action of diltiazem might be mediated, at least in part, by its effect on tissue oxidant/antioxidant status.
糖尿病肾病是终末期肾脏损害的主要原因。氧化应激参与了糖尿病肾病的病因学,据报道细胞内钙在糖尿病肾病肾脏损害的发展中起重要作用。钙拮抗作用可减缓糖尿病患者肾功能损害的进展。因此,本研究旨在探讨非二氢吡啶类钙通道阻滞剂地尔硫䓬对链脲佐菌素(STZ)诱导的糖尿病大鼠肾功能、氧化应激和一氧化氮(NO)释放的影响。通过单次腹腔注射STZ(65mg/kg)诱导大鼠糖尿病。STZ注射4周后,将大鼠分为四组:对照组大鼠、生理盐水治疗的糖尿病大鼠,以及两组分别从STZ注射4周后开始用5mg/kg和10mg/kg地尔硫䓬腹腔注射治疗8周的糖尿病大鼠。通过肌酐、血尿素氮、肌酐清除率和尿素清除率评估肾功能。通过肾脏丙二醛(MDA)、还原型谷胱甘肽(GSH)、超氧化物歧化酶(SOD)和过氧化氢酶测量氧化应激。我们还测量了肾脏亚硝酸盐水平。8周结束时,与对照组大鼠相比,糖尿病大鼠表现出肾功能障碍,表现为肌酐和尿素清除率降低以及白蛋白排泄率增加。肾脏的生化分析显示,糖尿病大鼠脂质过氧化增加,关键抗氧化酶GSH、SOD和过氧化氢酶活性降低,氧化应激显著增加。糖尿病大鼠的NO释放也显著高于对照组。与未治疗的糖尿病大鼠相比,糖尿病大鼠长期用地尔硫䓬治疗可显著减轻肾功能障碍和氧化应激,并增加NO水平。糖尿病大鼠的肾脏显示出形态学变化,如透明管型、肾小球增厚、中度间质纤维化和小动脉病变,而地尔硫䓬给药明显预防了糖尿病引起的肾脏形态学改变。本研究表明,糖尿病肾脏中氧化应激/亚硝化应激增加,钙通道阻滞可预防这些变化。结果还表明,在STZ诱导的糖尿病大鼠中,地尔硫䓬的保护作用可能至少部分是通过其对组织氧化/抗氧化状态的影响介导的。